title: Dose-dependent effect of niceritrol on plasma lipoprotein-a.
abstract: Lipoprotein-a, Lp(a), is a variant form of low density lipoprotein (LDL) that contains apolipoprotein-a, whose structure has 75-85% homology with plasminogen. Elevated plasma levels of Lp(a) are considered to be one of the independent risk factors for cardiovascular disease. We studied the effects of niceritrol, a nicotinic acid derivative, on plasma Lp(a) levels in 72 patients with hypercholesterolaemia. The dose of niceritrol was increased every 4 weeks, from 750 to 1500 and then to 2250 mg day-1. The final dose was adjusted to obtain a plasma cholesterol level less than 5.69 mmol l-1. Niceritrol led to significant decreases in plasma levels of median Lp(a), from 16.1 mg dl-1 (interquartile intervals, 8.7 to 32.8) to 11.1 mg dl-1 (interquartile intervals, 6.6 to 21), the mean reduction rate being 17.6%. In the group with pretreatment Lp(a) levels of over 20 mg dl-1, Lp(a) decreased by 10.0, 22.0 and 31.8% at the doses of 750, 1500, and 2250 mg day-1, respectively. In the group with levels less than 20 mg dl-1, only the dose of 2250 mg day-1 was effective in the reduction of Lp(a). The results suggest that the reduction of Lp(a) was dependent on the dose of niceritrol and on the pretreatment level of Lp(a). In conclusion, niceritrol is effective, in a dose-dependent manner, for reducing Lp(a) levels.
authors.affiliation: First Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Teramoto
authors.forename: N
authors.initials: N
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Shimano
authors.forename: Y
authors.initials: Y
authors.lastname: Oka
authors.forename: H
authors.initials: H
authors.lastname: Itakura
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
authors.forename: N
authors.initials: N
authors.lastname: Morisaki
authors.forename: K
authors.initials: K
authors.lastname: Shirai
authors.forename: T
authors.initials: T
authors.lastname: Ishikawa
authors.forename: N
authors.initials: N
authors.lastname: Tada
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Yamanouchi
authors.forename: T
authors.initials: T
authors.lastname: Matsushima
authors.forename: M
authors.initials: M
authors.lastname: Kawakami
authors.forename: T
authors.initials: T
authors.lastname: Murase
authors.forename: M
authors.initials: M
authors.lastname: Okubo
authors.forename: Y
authors.initials: Y
authors.lastname: Totsuka
authors.forename: M
authors.initials: M
authors.lastname: Kikuchi
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017270:Lipoprotein(a) / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009531:Niceritrol / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents; D017270:Lipoprotein(a); D009531:Niceritrol